Supplements

Highlights from a Presentation at the 32nd Annual Hawaii Dermatology SeminarTM. Waikoloa, Hawaii, March 1-7, 2008.
A supplement to Skin & Allergy News supported by an educational grant from OrthoNeutrogena..
This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News.

• Faculty/Faculty Disclosures
• Educational Reviewer
• Target Audience
• Educational Needs
• Learning Objectives
• Accreditation

To view the supplement, click the image above.
Faculty/Faculty Disclosure

James Q. Del Rosso, DO, MD
Clinical Associate Professor, Dermatology
University of Nevada School of Medicine
Las Vegas, Nevada
Touro University Nevada College of Osteopathic Medicine
Henderson, Nevada
Dermatology Residency Director
Valley Hospital Medical Center
Las Vegas, Nevada
Dr. Del Rosso has received grant/research support, has been a consultant, and has served on the speaker's bureau of OrthoNeutrogena, Medicis Pharmaceutical Corporation, Stiefel Laboratories, Inc., Ranbaxy Pharmaceuticals Inc., and Galderma Laboratories, L.P. In this supplement, Dr. Del Rosso will reference unlabeled/unapproved uses of sertaconazole 2% cream.
Educational Reviewer

Ronald K. Miller, PhD
Dr. Miller has nothing to disclose.
Target Audience

This educational activity has been developed for dermatologists, podiatrists, and other health care professionals who treat patients diagnosed with superficial fungal infections.
Educational Needs

Superficial fungal infections can be caused by a broad spectrum of fungal pathogens including dermatophytes, yeasts, and molds and can usually be treated successfully with topical antifungal therapy. Diagnosis of superficial fungal infections is commonly based on location and characteristics of the lesions. However, care must be taken to differentiate fungal infections caused by dermatophytes from those caused by yeasts, such asCandidaorMalassezia. In addition, most cutaneous infections involve itching and may further involve secondary bacterial infection. Depending on the nature of the infection and the patient's symptoms, treatment of cutaneous fungal infections requires consideration of many factors. For example, mixed infections with multiple causes require the use of broad-spectrum anti-infective agents, while symptoms such as itching and secondary bacterial infection require the use of topical remedies with both anti-inflammatory and antipruritic properties.

Sertaconazole nitrate, an imidazole antifungal agent, has demonstrated a broad spectrum of activity against multiple fungal organisms, including dermatophytes and yeasts, such asCandidaandMalassezia. This compound may exhibit fungicidal activity that is not concentration- and organism-dependent. Although sertaconazole 2% cream is approved in the United States for treatment of tinea pedis, multiple studies support its use for other cutaneous dermatophyte infections, cutaneous candidiasis, tinea versicolor, and seborrheic dermatitis. In addition to antifungal activity, sertaconazole nitrate has been shown to exhibit anti-inflammatory and antipruritic activity in multiple laboratory studies. These properties may relate to more rapid reduction in symptoms in the clinical setting. Understanding these unique properties of sertaconazole may improve patient care in the treatment of superficial fungal infections.
Learning Objectives

By reading and studying this supplement, participants should be prepared to:
• Name three organisms that are targeted by sertaconazole.
• Describe the anti-inflammatory and antibacterial properties of sertaconazole.
• Discuss the clinical trial results of sertaconazole for the treatment of a variety of fungal infections, including tinea pedis, tinea versicolor, and intertrigo.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin & Allergy News. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

The EOCME designated this educational supplement for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval: July 2008 - July 31, 2009.

Copyright © 2008 by Elsevier Inc.

Highlights from a Presentation at the 32nd Annual Hawaii Dermatology SeminarTM. Waikoloa, Hawaii, March 1-7, 2008.
A supplement to Skin & Allergy News supported by an educational grant from OrthoNeutrogena..
This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News.

• Faculty/Faculty Disclosures
• Educational Reviewer
• Target Audience
• Educational Needs
• Learning Objectives
• Accreditation

To view the supplement, click the image above.
Faculty/Faculty Disclosure

James Q. Del Rosso, DO, MD
Clinical Associate Professor, Dermatology
University of Nevada School of Medicine
Las Vegas, Nevada
Touro University Nevada College of Osteopathic Medicine
Henderson, Nevada
Dermatology Residency Director
Valley Hospital Medical Center
Las Vegas, Nevada
Dr. Del Rosso has received grant/research support, has been a consultant, and has served on the speaker's bureau of OrthoNeutrogena, Medicis Pharmaceutical Corporation, Stiefel Laboratories, Inc., Ranbaxy Pharmaceuticals Inc., and Galderma Laboratories, L.P. In this supplement, Dr. Del Rosso will reference unlabeled/unapproved uses of sertaconazole 2% cream.
Educational Reviewer

Ronald K. Miller, PhD
Dr. Miller has nothing to disclose.
Target Audience

This educational activity has been developed for dermatologists, podiatrists, and other health care professionals who treat patients diagnosed with superficial fungal infections.
Educational Needs

Superficial fungal infections can be caused by a broad spectrum of fungal pathogens including dermatophytes, yeasts, and molds and can usually be treated successfully with topical antifungal therapy. Diagnosis of superficial fungal infections is commonly based on location and characteristics of the lesions. However, care must be taken to differentiate fungal infections caused by dermatophytes from those caused by yeasts, such asCandidaorMalassezia. In addition, most cutaneous infections involve itching and may further involve secondary bacterial infection. Depending on the nature of the infection and the patient's symptoms, treatment of cutaneous fungal infections requires consideration of many factors. For example, mixed infections with multiple causes require the use of broad-spectrum anti-infective agents, while symptoms such as itching and secondary bacterial infection require the use of topical remedies with both anti-inflammatory and antipruritic properties.

Sertaconazole nitrate, an imidazole antifungal agent, has demonstrated a broad spectrum of activity against multiple fungal organisms, including dermatophytes and yeasts, such asCandidaandMalassezia. This compound may exhibit fungicidal activity that is not concentration- and organism-dependent. Although sertaconazole 2% cream is approved in the United States for treatment of tinea pedis, multiple studies support its use for other cutaneous dermatophyte infections, cutaneous candidiasis, tinea versicolor, and seborrheic dermatitis. In addition to antifungal activity, sertaconazole nitrate has been shown to exhibit anti-inflammatory and antipruritic activity in multiple laboratory studies. These properties may relate to more rapid reduction in symptoms in the clinical setting. Understanding these unique properties of sertaconazole may improve patient care in the treatment of superficial fungal infections.
Learning Objectives

By reading and studying this supplement, participants should be prepared to:
• Name three organisms that are targeted by sertaconazole.
• Describe the anti-inflammatory and antibacterial properties of sertaconazole.
• Discuss the clinical trial results of sertaconazole for the treatment of a variety of fungal infections, including tinea pedis, tinea versicolor, and intertrigo.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin & Allergy News. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

The EOCME designated this educational supplement for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval: July 2008 - July 31, 2009.

Copyright © 2008 by Elsevier Inc.

Highlights from a Presentation at the 32nd Annual Hawaii Dermatology SeminarTM. Waikoloa, Hawaii, March 1-7, 2008.
A supplement to Skin & Allergy News supported by an educational grant from OrthoNeutrogena..
This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News.

• Faculty/Faculty Disclosures
• Educational Reviewer
• Target Audience
• Educational Needs
• Learning Objectives
• Accreditation

To view the supplement, click the image above.
Faculty/Faculty Disclosure

James Q. Del Rosso, DO, MD
Clinical Associate Professor, Dermatology
University of Nevada School of Medicine
Las Vegas, Nevada
Touro University Nevada College of Osteopathic Medicine
Henderson, Nevada
Dermatology Residency Director
Valley Hospital Medical Center
Las Vegas, Nevada
Dr. Del Rosso has received grant/research support, has been a consultant, and has served on the speaker's bureau of OrthoNeutrogena, Medicis Pharmaceutical Corporation, Stiefel Laboratories, Inc., Ranbaxy Pharmaceuticals Inc., and Galderma Laboratories, L.P. In this supplement, Dr. Del Rosso will reference unlabeled/unapproved uses of sertaconazole 2% cream.
Educational Reviewer

Ronald K. Miller, PhD
Dr. Miller has nothing to disclose.
Target Audience

This educational activity has been developed for dermatologists, podiatrists, and other health care professionals who treat patients diagnosed with superficial fungal infections.
Educational Needs

Superficial fungal infections can be caused by a broad spectrum of fungal pathogens including dermatophytes, yeasts, and molds and can usually be treated successfully with topical antifungal therapy. Diagnosis of superficial fungal infections is commonly based on location and characteristics of the lesions. However, care must be taken to differentiate fungal infections caused by dermatophytes from those caused by yeasts, such asCandidaorMalassezia. In addition, most cutaneous infections involve itching and may further involve secondary bacterial infection. Depending on the nature of the infection and the patient's symptoms, treatment of cutaneous fungal infections requires consideration of many factors. For example, mixed infections with multiple causes require the use of broad-spectrum anti-infective agents, while symptoms such as itching and secondary bacterial infection require the use of topical remedies with both anti-inflammatory and antipruritic properties.

Sertaconazole nitrate, an imidazole antifungal agent, has demonstrated a broad spectrum of activity against multiple fungal organisms, including dermatophytes and yeasts, such asCandidaandMalassezia. This compound may exhibit fungicidal activity that is not concentration- and organism-dependent. Although sertaconazole 2% cream is approved in the United States for treatment of tinea pedis, multiple studies support its use for other cutaneous dermatophyte infections, cutaneous candidiasis, tinea versicolor, and seborrheic dermatitis. In addition to antifungal activity, sertaconazole nitrate has been shown to exhibit anti-inflammatory and antipruritic activity in multiple laboratory studies. These properties may relate to more rapid reduction in symptoms in the clinical setting. Understanding these unique properties of sertaconazole may improve patient care in the treatment of superficial fungal infections.
Learning Objectives

By reading and studying this supplement, participants should be prepared to:
• Name three organisms that are targeted by sertaconazole.
• Describe the anti-inflammatory and antibacterial properties of sertaconazole.
• Discuss the clinical trial results of sertaconazole for the treatment of a variety of fungal infections, including tinea pedis, tinea versicolor, and intertrigo.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin & Allergy News. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

The EOCME designated this educational supplement for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval: July 2008 - July 31, 2009.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 32ndHawaii Dermatology SeminarTMand the Cosmetic Dermatology SeminarTM.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.
Topic Highlights

• Evolution of Fillers Continues at a Rapid Pace
• Development of Fractional Laser Devices: Challenging Clinicians to Keep Pace
• Future Laser May Hit Fat Target
• Extend Cosmetic Offerings to Medical Patients
• 'Mini-Face-Lift' Is in Realm of Cosmetic Surgery
• Injectables Menu Offers Options for Most Patients
• Botanical Products Move to Front of Cosmeceuticals Class
• Bromelain (Pineapple Extract)
• Fractional Laser Side Effect Risk Low, Study Finds
• Fillers Changing Cosmetic Approach
Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, New York
Dr. Goldberg has nothing to disclose.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Irvine, California
Dr. Zachary has nothing to disclose.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 32ndHawaii Dermatology SeminarTMand the Cosmetic Dermatology SeminarTM.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.
Topic Highlights

• Evolution of Fillers Continues at a Rapid Pace
• Development of Fractional Laser Devices: Challenging Clinicians to Keep Pace
• Future Laser May Hit Fat Target
• Extend Cosmetic Offerings to Medical Patients
• 'Mini-Face-Lift' Is in Realm of Cosmetic Surgery
• Injectables Menu Offers Options for Most Patients
• Botanical Products Move to Front of Cosmeceuticals Class
• Bromelain (Pineapple Extract)
• Fractional Laser Side Effect Risk Low, Study Finds
• Fillers Changing Cosmetic Approach
Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, New York
Dr. Goldberg has nothing to disclose.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Irvine, California
Dr. Zachary has nothing to disclose.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 32ndHawaii Dermatology SeminarTMand the Cosmetic Dermatology SeminarTM.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.
Topic Highlights

• Evolution of Fillers Continues at a Rapid Pace
• Development of Fractional Laser Devices: Challenging Clinicians to Keep Pace
• Future Laser May Hit Fat Target
• Extend Cosmetic Offerings to Medical Patients
• 'Mini-Face-Lift' Is in Realm of Cosmetic Surgery
• Injectables Menu Offers Options for Most Patients
• Botanical Products Move to Front of Cosmeceuticals Class
• Bromelain (Pineapple Extract)
• Fractional Laser Side Effect Risk Low, Study Finds
• Fillers Changing Cosmetic Approach
Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, New York
Dr. Goldberg has nothing to disclose.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Irvine, California
Dr. Zachary has nothing to disclose.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

•Table of Contents
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

•Table of Contents
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

•Table of Contents
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by OrthoNeutrogena. The content of this supplement was developed from a roundtable program.

•Faculty/Faculty Disclosures
•Roundtable Participants

To view the supplement, click the image above.

• The Mechanisms of Wound Healing
• The Role of the Macrophage in Wound Healing
• Treatment of Actinic Keratoses and Nonmelanoma Skin Cancer Lesions
• The Use of a Topical Emulsion for Wound Healing
• Radiation Dermatitis
• The Use of a Topical Emulsion for Treatment of Radiation Dermatitis
Faculty/Faculty Disclosures

Joel L. Cohen, MD
Assistant Clinical Professor
Department of Dermatology
University of Colorado
Englewood, Colo.
Dr. Cohen has disclosed that he is a consultant to Johnson & Johnson.

Joseph L. Jorizzo, MD
Professor, Founding and Former Chair
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, N.C.
Dr. Jorizzo has nothing to disclose.

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana School of Medicine
Medical Director
DermResearch, PLLC
Louisville, Ky.
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd. Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Roundtable Participants

Linda Carlin, RN, MS, OCn
CJW Medical Center
Richmond Va.

Sharon R. Hymes, MD
University of Texas
Anderson Cancer Center
Houston, Tex.

Tania J. Phillips, MD
Boston University School of Medicine
Boston, Mass.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by OrthoNeutrogena. The content of this supplement was developed from a roundtable program.

•Faculty/Faculty Disclosures
•Roundtable Participants

To view the supplement, click the image above.

• The Mechanisms of Wound Healing
• The Role of the Macrophage in Wound Healing
• Treatment of Actinic Keratoses and Nonmelanoma Skin Cancer Lesions
• The Use of a Topical Emulsion for Wound Healing
• Radiation Dermatitis
• The Use of a Topical Emulsion for Treatment of Radiation Dermatitis
Faculty/Faculty Disclosures

Joel L. Cohen, MD
Assistant Clinical Professor
Department of Dermatology
University of Colorado
Englewood, Colo.
Dr. Cohen has disclosed that he is a consultant to Johnson & Johnson.

Joseph L. Jorizzo, MD
Professor, Founding and Former Chair
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, N.C.
Dr. Jorizzo has nothing to disclose.

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana School of Medicine
Medical Director
DermResearch, PLLC
Louisville, Ky.
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd. Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Roundtable Participants

Linda Carlin, RN, MS, OCn
CJW Medical Center
Richmond Va.

Sharon R. Hymes, MD
University of Texas
Anderson Cancer Center
Houston, Tex.

Tania J. Phillips, MD
Boston University School of Medicine
Boston, Mass.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by OrthoNeutrogena. The content of this supplement was developed from a roundtable program.

•Faculty/Faculty Disclosures
•Roundtable Participants

To view the supplement, click the image above.

• The Mechanisms of Wound Healing
• The Role of the Macrophage in Wound Healing
• Treatment of Actinic Keratoses and Nonmelanoma Skin Cancer Lesions
• The Use of a Topical Emulsion for Wound Healing
• Radiation Dermatitis
• The Use of a Topical Emulsion for Treatment of Radiation Dermatitis
Faculty/Faculty Disclosures

Joel L. Cohen, MD
Assistant Clinical Professor
Department of Dermatology
University of Colorado
Englewood, Colo.
Dr. Cohen has disclosed that he is a consultant to Johnson & Johnson.

Joseph L. Jorizzo, MD
Professor, Founding and Former Chair
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, N.C.
Dr. Jorizzo has nothing to disclose.

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana School of Medicine
Medical Director
DermResearch, PLLC
Louisville, Ky.
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd. Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Roundtable Participants

Linda Carlin, RN, MS, OCn
CJW Medical Center
Richmond Va.

Sharon R. Hymes, MD
University of Texas
Anderson Cancer Center
Houston, Tex.

Tania J. Phillips, MD
Boston University School of Medicine
Boston, Mass.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Ferndale Laboratories. The articles in this supplement are based on faculty interviews.

•Topics/Faculty

To view the supplement, click the image above.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Ky
Dr. Kircik has disclosed that he has received research support from, is a consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Poster Review
* Patient Demographics and Baseline Characteristics
* Clinical Assessments
* Safety Evaluation
* Results
* Adverse Events
* Summary by Dr. Kircik

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Ferndale Laboratories. The articles in this supplement are based on faculty interviews.

•Topics/Faculty

To view the supplement, click the image above.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Ky
Dr. Kircik has disclosed that he has received research support from, is a consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Poster Review
* Patient Demographics and Baseline Characteristics
* Clinical Assessments
* Safety Evaluation
* Results
* Adverse Events
* Summary by Dr. Kircik

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Ferndale Laboratories. The articles in this supplement are based on faculty interviews.

•Topics/Faculty

To view the supplement, click the image above.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Ky
Dr. Kircik has disclosed that he has received research support from, is a consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Poster Review
* Patient Demographics and Baseline Characteristics
* Clinical Assessments
* Safety Evaluation
* Results
* Adverse Events
* Summary by Dr. Kircik

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Johnson & Johnson. The articles in this supplement are based on faculty interviews. This supplement is produced in affiliation with Skin Disease Education Foundation's Women's & Pediatric Dermatology Seminar 2007

A supplement to Skin & Allergy News and supported by Johnson & Johnson. The articles in this supplement are based on faculty interviews. This supplement is produced in affiliation with Skin Disease Education Foundation's Women's & Pediatric Dermatology Seminar 2007

A supplement to Skin & Allergy News and supported by Johnson & Johnson. The articles in this supplement are based on faculty interviews. This supplement is produced in affiliation with Skin Disease Education Foundation's Women's & Pediatric Dermatology Seminar 2007

A supplement to Skin & Allergy News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

•Topic Highlights
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

•Topic Highlights
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

•Topic Highlights
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.